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Abstract
Background—Salmonella causes an estimated 100 000 antimicrobial-resistant infections 
annually in the United States. Salmonella antimicrobial resistance may result in bacteremia and 
poor outcomes. We describe antimicrobial resistance among nontyphoidal Salmonella blood 
isolates, using data from the National Antimicrobial Resistance Monitoring System.
Methods—Human nontyphoidal Salmonella isolates from 2003 to 2013 were classified as fully 
susceptible, resistant to ≥1 antimicrobial agent, or resistant to a first-line agent. Logistic regression 
was used to compare resistance patterns, serotypes, and patient characteristics for Salmonella 
isolated from blood versus stool and to determine resistance trends over time.
Results—Approximately 20% of blood isolates had antimicrobial resistance to a first-line 
treatment agent. Bacteremia was associated with male sex, age ≥65 years, and specific serotypes. 
Blood isolates were more likely to be resistant to ≥1 agent for serotypes Enteritidis, Javiana, 
Panama, and Typhimurium. Blood isolates were most commonly resistant to tetracycline (19%), 
and more likely resistant to a first-line agent (odds ratio, 1.81; 95% confidence interval, 1.56–2.11) 
than stool isolates. Ceftriaxone resistance increased in blood isolates from 2003 to 2013 (odd ratio, 
1.12; 95% confidence interval, 1.02–1.22).
Conclusions—Resistance to first-line treatment agents in patients with Salmonella bacteremia is 
a concern for public health and for informing clinical decisions. Judicious antimicrobial use is 
crucial to limit resistance.
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Salmonella causes an estimated 1.2 million illnesses, 23 000 hospitalizations, and 450 deaths 
annually in the United States [1]. Nontyphoidal Salmonella enterica causes the majority of 
these infections and almost all Salmonella-related hospitalizations and deaths [2]. Most 
Salmonella infections result from the ingestion of contaminated food [2, 3] and are 
characterized by gastroenteritis. Invasive infection, such as bacteremia and meningitis, 
occurs most commonly in persons with compromised immunity [4], including those with 
human immunodeficiency virus infection [5], infants [6], and older adults, who may have 
increased risk of complications, including death [7, 8]. Invasive nontyphoidal Salmonella 
infection is most common among patients with serotypes Choleraesuis, Dublin, Enteritidis, 
Heidelberg, Poona, and Schwarzengrund [6].
Antimicrobial treatment can be life-saving for invasive Salmonella infections [2]. Antibiotics 
commonly prescribed for these infections include fluoroquinolones (eg, ciprofloxacin) or 
third-generation (extended-spectrum) cephalosporins (eg, ceftriaxone) [9]. Antimicrobial 
resistance may contribute to bacteremia, treatment failure, and poor clinical outcomes. 
Hospitalizations occur with increased frequency in persons with resistant isolates, 
particularly those with ceftriaxone resistance [10, 11]. Salmonella bacteremia is more 
common in drug-resistant than in susceptible infections [10–12]. For example, 
fluoroquinolone resistance is associated with a >3-fold increased risk of invasive illness or 
death within 90 days, and nalidixic acid resistance may correlate with ciprofloxacin 
treatment failure [13, 14]. In recent years, azithromycin use for nontyphoidal Salmonella 
treatment has increased, probably owing to increasing resistance to fluoroquinolones and 
extended-spectrum cephalosporins; however, there have been recent reports of azithromycin 
treatment failures [15]. The Clinical and Laboratory Standards Institute (CLSI) has not yet 
established a break point for azithromycin resistance for nontyphoidal Salmonella [3, 16].
Most nontyphoidal Salmonella infections are food borne. Resistance among nontyphoidal 
Salmonella has been linked to antimicrobial use in food animal production [17, 18]. 
Injudicious antimicrobial use among humans has also been linked to an increased risk of 
antimicrobial-resistant infection [19].
We describe and compare antimicrobial resistance patterns among nontyphoidal Salmonella 
blood and stool isolates and trends in antimicrobial resistance. We compare characteristics 
(sex and age) of persons with nontyphoidal Salmonella isolated from blood versus stool. We 
also assess the differences in blood isolation rates and resistance by serotype.
MATERIALS AND METHODS
The National Antimicrobial Resistance Monitoring System (NARMS) at the Centers for 
Disease Control and Prevention (CDC) has tracked resistance patterns among enteric 
pathogens from humans since 1996. NARMS is a collaboration among the CDC, the US 
Food and Drug Administration (FDA), the US Department of Agriculture, and state and 
local public health departments. Since 2003, NARMS has included health departments from 
all 50 states, covering >300 million persons [20]. Participating public health laboratories 
submit every 20th nontyphoidal Salmonella isolate to the CDC laboratory and include 
available information regarding age, sex, specimen source, and serotype.
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Isolates were tested in the CDC NARMS laboratory using broth microdilution (Sensititre; 
Trek Diagnostics, part of Thermo Fisher Scientific). The following antimicrobial agents 
were tested routinely via this method from 2003 through 2013: amoxicillin–clavulanic acid, 
ampicillin, cefoxitin, ceftiofur, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, 
kanamycin, nalidixic acid, streptomycin, sulfisoxazole/ sulfamethoxazole (sulfonamide), 
tetracycline, and trimethoprim-sulfamethoxazole (TMP-SMX). CLSI criteria were used for 
interpretation when available [21]. Azithromycin was not routinely tested before 2011. 
Before 2004, sulfamethoxazole was used instead of sulfisoxazole. NARMS break points 
were used for streptomycin (≥64 μg/mL) and azithromycin (≥32 μg/mL), which have no 
CLSI break points [20].
Isolates with specimen sources other than blood or stool and isolates of serotypes Typhi, 
Paratyphi A, Paratyphi B (var L+ tartrate–), and Paratyphi C were excluded from the 
analysis. Blood and stool isolates that were not serotyped, were partially serotyped, or were 
characterized as rough or nonmotile were also excluded. From this point forward, we refer to 
all nontyphoidal Salmonella isolates included in the analysis as Salmonella. All resistant 
isolates and isolates with an intermediate minimum inhibitory concentration were 
categorized as resistant to remain in accordance with clinical practice, except that we did not 
include isolates with intermediate minimum inhibitory concentrations among those with 
specific resistance pattern combinations (eg, resistance to ampicillin, streptomycin, 
sulfonamide, and tetracycline). CLSI interpretive criteria for ciprofloxacin changed in 2012 
to reflect clinical significance; susceptibility was defined as ≤0.06 μg/mL, intermediate 
resistance as 0.12–0.5 μg/mL, and resistance as ≥1.0 μg/mL.
We analyzed data on Salmonella isolated from 2003 through 2013. Patients with Salmonella 
isolated from blood and stool were compared by sex and age, using odds ratios (ORs) and 
95% confidence intervals (CIs). Patients were divided into 6 age groups: <1, 1–4, 5–17, 18–
64, 65–84, and ≥85 years. Non-Typhimurium blood and stool isolates were compared with 
serotype Typhimurium, which served as the referent group. Serotypes with <10 blood 
isolates were combined into a category called other. Blood and stool isolates were compared 
for antimicrobial resistance. We determined the number of isolates that were fully 
susceptible, resistant to ≥1 agent, resistant to ≥3 CLSI classes, and resistant to ≥5 CLSI 
classes. We also examined the following resistance pattern combinations: resistance to 
ampicillin, streptomycin, sulfonamide, and tetracycline but not chloramphenicol; resistance 
to ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline; resistance to 
ampicillin, chloramphenicol, streptomycin, sulfonamide, tetracycline, amoxicillin–
clavulanic acid, and ceftriaxone; and resistance to ampicillin, amoxicillin–clavulanic acid, 
and ceftriaxone. Resistance to a first-line treatment agent was defined as resistance to ≥1 of 
the following agents used to treat Salmonella infections: ampicillin, ceftriaxone, 
ciprofloxacin and TMP-SMX. Salmonella isolates from blood were compared with stool 
isolates for resistance to ≥1 agents by serotype using logistic regression.
Various regression models, including robust and logistic, were used to assess the sensitivity 
of the model choice and to identify specific trends. Estimated annual trends with associated 
CIs were then computed by agent and specimen source.
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RESULTS
During 2003–2013, we tested 23 761 Salmonella isolates. Of those, 21 390 were from blood 
or stool, 1388 (5.9%) were from urine, and the remaining 983 (4%) were from abscesses, 
gallbladders, wounds, or other sites. Overall, 524 blood and stool isolates were excluded 
from analysis; 264 were not serotyped, 200 were partially serotyped, and 60 were rough or 
nonmotile. Of the 20 866 remaining isolates, 1189 (5.7%) were from blood, and 19 677 
(94.3%) were from stool. Of 19 362 isolates with information on sex, 9774 (50.5%) were 
from female patients. Among 1117 blood isolates for which information on patient sex was 
available, 608 (54.4%) were from male patients, who were more likely to have bacteremia 
(OR, 1.23; 95% CI, 1.09–1.39).
The median age was 43 years (range, <1 to 98 years) among patients with blood isolates, 
compared with 22 years (<1 to 103 years) among those with stool isolates (P < .001). 
Persons aged 65–84 years (OR, 2.04; 95% CI, 1.73–2.41) or ≥85 years (OR, 2.10; 95% CI, 
1.47–3.00) were more likely to have bacteremia than those in the 18–64-year age group 
(referent). Infants <1 year old (OR, 0.77; 95% CI, .62–.97) and children aged 1–4 (OR, 0.63; 
95% CI, .52–.76) or 5–17 years (OR, 0.68; 95% CI, .56–.82) were less likely to have 
bacteremia.
The proportion of Salmonella isolates that came from blood varied by serotype, ranging 
from 87.0% for serotype Dublin to 2.3% for serotype Muenchen (Table 1). Compared with 
Typhimurium, the 3 serotypes most highly associated with bacteremia were Dublin (OR, 
128.2; 95% CI, 57.19–287.40), Sandiego (OR, 4.90; 95% CI, 2.90–8.29), and 
Schwarzengrund (OR, 3.44; 95% CI, 2.14–5.55). Serotypes Enteritidis, Heidelberg, 
Oranienburg, Panama, Poona, and Rubislaw were also more likely to be isolated from blood, 
and serotypes Javiana, Muenchen, and Newport were less likely to be isolated from blood.
Blood isolates were further characterized by resistance pattern; 868 (73.0%) of 1189 blood 
isolates were susceptible to all agents tested. Among the 321 blood isolates that were 
resistant to ≥1 agent, resistance to a first-line treatment agent was found in 237 (73.8%). 
Compared with stool isolates, blood isolates were associated with resistance to ≥1 agent, ≥3 
classes, ≥5 classes, and first-line treatment agents. Isolation from blood was also 
significantly associated with resistance to most other agents and resistance pattern 
combinations (Table 2).
Of the 237 blood isolates with resistance to a first-line treatment agent, the most common 
serotypes were Typhimurium (85 isolates), Heidelberg (38 isolates), and Dublin (33 
isolates). Serotypes Dublin, Heidelberg, and Newport had the greatest number of blood 
isolates resistant to ceftriaxone. Serotypes Typhimurium, Heidelberg, and Dublin had the 
greatest number resistant to ampicillin, serotype Enteritidis had the greatest number resistant 
to ciprofloxacin, and serotype Typhimurium had the greatest number resistant to TMP-SMX 
(see Supplementary Data).
The following serotypes had the strongest association between resistance to ≥1 agent and 
isolation from blood: Panama (OR, 6.85; 95% CI, 1.25–37.58), Javiana (OR, 3.76; 95% CI, 
1.08–13.04), Typhimurium (OR, 2.04; 95% CI, 1.52–2.73), and Enteritidis (OR, 1.61; 95% 
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CI, 1.13–2.29) (Table 3). In contrast, for serotype I 4,[5],12:i:–, stool isolates were 
significantly more likely than blood isolates to be associated with resistance to ≥1 
antimicrobial agent.
During 2003–2013, ciprofloxacin resistance increased and ampicillin resistance decreased 
for both blood and stool isolates, though the trends were statistically significant only for 
stool isolates (Table 4). In contrast, ceftriaxone resistance increased significantly for blood 
isolates (OR, 1.12; 95% CI, 1.02–1.22) and decreased significantly for stool isolates (OR, 
0.95; 95% CI, .92–.97). Resistance to TMP-SMX did not change significantly for blood or 
stool isolates.
DISCUSSION
We found a substantial amount of resistance to antimicrobials used for Salmonella 
bloodstream infections. Overall, approximately 5% of all Salmonella isolates that came from 
blood were resistant to ceftriaxone. Resistance to ceftriaxone has doubled since a 1996–2007 
study from NARMS. In that study, only 2.5% of all Salmonella isolates that came from 
blood were resistant to ceftriaxone [12]. Ceftriaxone is considered a first-line treatment for 
Salmonella bacteremia, and increasing antimicrobial resistance is concerning for clinical 
treatment and patient outcomes. If this path of increasing resistance continues, we may soon 
be at a crossroads where first-line treatment recommendations will need to change, as 
occurred with gonorrhea treatment and the use of cefixime; resistance increased from 0.1% 
to 1.5% over 5 years and prompted a change in gonorrhea treatment guidelines [22].
Fluoroquinolones, penicillins, and cephalosporins are commonly prescribed for a variety of 
clinical syndromes, and increasing human exposure to these antimicrobials may lead to an 
increased risk of antimicrobial resistance [10, 15, 23]. Since the previous NARMS study, 
fluoroquinolone resistance has nearly doubled. We also found that resistance to ampicillin, 
Salmonella bacteremia. Nalidixic acid resistance correlates with resistance to ciprofloxacin 
and may predict treatment failure [12, 14]. We found that 4% of all Salmonella isolates that 
came from blood had nalidixic acid resistance and 4.5% had ciprofloxacin resistance; the 
NARMS study from 1996–2007 found that 2.7% of all Salmonella isolates that came from 
blood were resistant to nalidixic acid [12]. Resistance to ≥1 agent, and resistance to ≥3 or ≥5 
classes of antimicrobials were also associated with bacteremia, supporting the finding that 
bacteremia is more common in drug-resistant infections than susceptible ones [10–12]. We 
do not know the relative contribution of each biological or clinical mechanism that may link 
antimicrobial resistance to bloodstream infections; these infections might be due to the 
failure or reduced efficacy of empirical antimicrobial treatment which would result in more 
severe illness, the presence of additional virulence factors that could enhance invasiveness 
and worsen patient outcome, or the fact that patients whose isolates are submitted to 
NARMS for testing are inherently more likely to be hospitalized and seek care from a 
provider owing to increased severity of symptoms [11].
The annual proportion of isolates that came from blood with ceftriaxone resistance increased 
from 2003 through 2013, whereas the proportion of stool isolates with ceftriaxone resistance 
decreased. This finding did not hold for the other first-line treatment agents. The reason that 
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blood isolates are increasingly resistant to ceftriaxone whereas stool isolates are becoming 
more susceptible to ceftriaxone is probably related to serotype. It is likely that the overall 
distribution of Salmonella serotypes in blood and stool is constantly evolving, and serotypes 
that are commonly resistant may be increasing disproportionally in blood over time. For 
example, host adapted, highly resistant serotypes have become associated with Salmonella 
blood infections, particularly serotypes Dublin and Choleraesuis [24–26]. Salmonella 
Choleraesuis, a serotype that is host adapted to swine, is becoming increasingly resistant, 
probably owing to various resistance genes and plasmids [25, 26], possibly acquired through 
agricultural antimicrobial use.
In our study, bacteremia was most common among patients with serotypes Dublin, 
Sandiego, Schwarzengrund, Poona, Panama, Heidelberg, Oranienburg, Rubislaw, and 
Enteritidis, compared with serotype Typhimurium. These serotype-specific findings are 
consistent with previous studies, with the notable exceptions of serotypes Poona and 
Rubislaw. A previous study showed a higher risk of invasive disease for serotype Poona 
compared with Typhimurium [6], but other studies have not supported this association [11, 
12, 27]. Previous studies have not shown an association between bacteremia and serotype 
Rubislaw [6, 11, 12, 27]. The reason for the incongruous findings for serotype Poona and the 
new association of bacteremia with serotype Rubislaw is unknown. Most of the infections 
with serotypes Rubislaw and Poona in our study were among children. Both these serotypes 
have an historical association with reptiles [28], and reptile-associated Salmonella infections 
may place children at an increased risk of invasive infection [29]. This may explain the 
increased blood isolation of Rubislaw and Poona isolates in our study and may indicate that 
reptile exposures predispose to Salmonella bacteremia with certain serotypes.
We confirmed findings from previous studies regarding risk factors for Salmonella 
bacteremia, including a higher frequency of Salmonella bacteremia in men than in women, a 
higher median age among patients with bacteremia than among patients with stool isolates, 
and the highest rate of bacteremia among persons aged ≥64 years, consistent with invasive 
disease being more common in older adults [12]. Other risk factors, such as international 
travel, have been associated with antimicrobial resistance in patients with Salmonella 
bacteremia, [30],but travel data are not collected in NARMS. This study and a previous one 
that used NARMS data [12] found that the odds of Salmonella bacteremia was lower among 
infants aged <1 year than among adults aged 18–64 years. This may be due in part to 
differences in Salmonella serotype distribution. For example, in our study a lower proportion 
of infants than adults had Salmonella Enteriditis, which is known to be an invasive serotype 
[6,27]. Moreover, in contrast to adults with Salmonella gastroenteritis, it is recommended 
that infants <3 months of age receive treatment to avert invasive disease [31]. Further 
investigation is needed to characterize the vulnerability of infants to Salmonella bacteremia.
This study had some limitations. The NARMS protocol for the state and local laboratories 
requires submission of every 20th Salmonella isolate to the CDC. It is possible that some 
patients who had a stool isolate submitted to CDC NARMS also had bacteremia, but the 
stool isolate was the 20th isolate submitted by the health department to CDC NARMS. This 
would bias our associations toward the null. Differential resistance among the missing and 
interaction between variables, possibly regarding both serotype and age, may influence 
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results. We were unable to examine serotypes with regard to virulence as an explanation for 
their propensity cause bacteremia (or lack thereof) to. NARMS does not capture patient 
treatment or outcome data. For serotypes with small numbers of isolates, limited precise 
estimates of antimicrobial resistance could not be made because of limited power. We were 
also limited by the short time series of 11 years (2003–2013) to perform time trends 
analysis.
In conclusion, Salmonella blood isolates were more likely than stool isolates to be resistant 
to ≥1 agent and to first-line treatment agents. Resistance to first-line treatment agents in 
patients with Salmonella bacteremia is a concern for public health and clinical outcomes and 
is important for informing clinical decisions regarding appropriate treatment. Judicious 
antimicrobial use in both humans and food-producing animals is crucial to limit the 
emergence and spread of resistance.
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Table 1.
Proportion of Nontyphoidal Salmonella Isolates From Blood by Serotype, 2003–2013
Serotypea Total Isolates, No. Blood Isolates, No. (%) OR (95% CI)
Dublin 54 47 (87.0) 128.20 (57.19–287.40)
Sandiego 93 19 (20.4) 4.90 (2.90–8.29)
Schwarzengrund 144 22 (15.3) 3.44 (2.14–5.55)
Poona 172 26 (15.1) 3.40 (2.19–5.29)
Panama 108 16 (14.8) 3.32 (1.92–5.76)
Heidelberg 811 119 (14.7) 3.28 (2.58–4.19)
Oranienburg 399 44 (11.0) 2.37 (1.68–3.34)
Rubislaw 99 10 (10.1) 2.15 (1.10–4.19)
Enteritidis 3908 250 (6.4) 1.31 (1.08–1.59)
Montevideo 549 31 (5.7) 1.14 (.77–1.69)
Other 4320 220 (5.1) 1.03 (.84–1.25)
Saintpaul 490 25 (5.1) 1.03 (.67–1.58)
Paratyphi B var L+ tartrate+ 348 14 (4.0) 0.80 (.46–1.39)
Agona 286 11 (3.9) 0.76 (.41–1.42)
I 4,[5],12:i:– 790 28 (3.5) 0.70 (.47–1.05)
Infantis 446 14 (3.1) 0.62 (.36–1.08)
Newport 2398 64 (2.7) 0.52 (.39–.70)
Javiana 1159 28 (2.4) 0.47 (.32–.71)
Muenchen 474 11 (2.3) 0.45 (.25–.84)
Typhimurium 3818 190 (5.0) Referent
Total 20 866 1189 (5.7)
Abbreviations: CI, confidence interval; OR, odds ratio.
aSalmonella serotypes with ≥10 blood isolates are listed individually, and those with <10 blood isolates are listed in the “Other” category.
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Table 2.
Proportion of Nontyphoidal Salmonella Isolates From Blood by Antimicrobial Resistance Type, 2003–2013
Antimicrobial Resistance Typea Total Isolates, No. Blood Isolates, No. (%) OR (95% CI)
Fully susceptible 16 972 868 (5.1) Referent
Agents
 Amoxicillin-clavulanic acid 1478 120 (8.1) 1.64(1.34–2.00)
 Ampicillin 2194 201 (9.2) 1.87 (1.59–2.20)
 Azithromycinb 7 1 (14.3) 3.09 (.37–25.71)
 Cefoxitin 712 59 (8.3) 1.68(1.27–2.21)
 Ceftiofur 686 56 (8.2) 1.65(1.24–2.19)
 Ceftriaxone 677 55 (8.1) 1.64 (1.24–2.18)
 Chloramphenicol 1423 136 (9.6) 1.96 (1.62–2.37)
 Ciprofloxacin 526 53 (10.1) 2.08 (1.55–2.78)
 Gentamicin 355 34 (9.6) 1.97 (1.37–2.82)
 Kanamycin 493 70(14.2) 3.07 (2.36–3.99)
 Nalidixic acid 426 48 (11.3) 2.36 (1.73–3.21)
 Streptomycin 2199 194 (8.8) 1.80 (1.53–2.11)
 Sulfamethoxazole or sulfisoxazolec 2289 192 (8.4) 1.70(1.44–2.00)
 Tetracycline 2695 227 (8.4) 1.71 (1.47–1.99)
 TMP-SMX 326 34 (10.4) 2.16 (1.51–3.10)
Patterns
 First-line agentd 2663 237 (8.9) 1.81 (1.56–2.11)
 ≥1 agent 3894 321 (8.3) 1.67 (1.46–1.91)
 ≥3 classes 2276 205 (9.0) 1.84(1.57–2.15)
 ≥5 classes 1378 133 (9.7) 1.98 (1.64–2.40)
 ACSSuT 1170 105 (9.0) 1.83 (1.48–2.26)
 ACSSuTAuCx 395 30 (7.6) 1.53 (1.04–2.23)
 ASSuTnoC 283 20 (7.1) 1.41 (.89–2.24)
 AAuCx 647 53 (8.2) 1.66 (1.24–2.21)
Abbreviations: AAuCx, resistant to at least ampicillin, amoxicillin–clavulanic acid, and ceftriaxone; ACSSuT, resistant to at least ampicillin, 
chloramphenicol, streptomycin, a sulfonamide, and tetracycline; ACSSuTAuCx, resistant to at least ACSSuT, amoxicillin–clavulanic acid, and 
ceftriaxone; ASSuTnoC, resistant to at least ampicillin, streptomycin, a sulfonamide, and tetracycline, but not chloramphenicol; CI, confidence 
interval; OR, odds ratio; TMP-SMX, trimethoprim-sulfamethoxazole.
a
For single antimicrobials and resistance to ≥1 agent, ≥3 classes, or ≥5 classes, resistance is defined as an intermediate or resistant minimum 
inhibitory concentration.
bAzithromycin was not routinely tested before 2011.
cSulfamethoxazole, which was tested before 2004 to represent sulfonamides, was replaced by sulfisoxazole in 2004.
d
Resistant to ≥1 of the following agents: ampicillin, ceftriaxone, ciprofloxacin, or TMP-SMX.
J Infect Dis. Author manuscript; available in PMC 2019 July 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Angelo et al. Page 12
Ta
bl
e 
3.
A
nt
im
ic
ro
bi
al
 R
es
ist
an
ce
 o
f N
on
ty
ph
oi
da
l S
alm
on
ell
a B
lo
od
 a
nd
 S
to
ol
 Is
ol
at
es
, b
y 
Se
ro
ty
pe
, 2
00
3–
20
13
Bl
oo
d 
Is
ol
at
es
St
oo
l I
so
la
te
s
Se
ro
ty
pe
To
ta
l, 
N
o.
R
es
ist
an
t, 
N
o.
 (%
)a
To
ta
l, 
N
o.
R
es
ist
an
t, 
N
o.
 (%
)a
O
R
 (9
5%
 C
I)
En
te
rit
id
is
25
0
40
 (1
6.0
)
36
58
38
7 
(10
.6)
1.
61
 (1
.13
–2
.29
)
Ty
ph
im
ur
iu
m
19
0
10
1 
(53
.2)
36
28
12
99
 (3
5.8
)
2.
04
 (1
.52
–2
.73
)
H
ei
de
lb
er
g
11
9
52
 (4
3.7
)
69
2
27
9 
(40
.3)
1.
15
 (.7
8–
1.7
0)
N
ew
po
rt
64
9 
(14
.1)
23
34
31
1 
(13
.3)
1.
06
 (.5
2–
2.1
8)
D
ub
lin
47
35
 (7
4.5
)
7
5 
(71
.4)
1.
17
 (.2
0–
6.8
2)
O
ra
ni
en
bu
rg
44
3 
(6.
8)
35
5
18
 (5
.1)
1.
37
 (.3
9–
4.8
5)
M
on
te
v
id
eo
31
1 
(3.
2)
51
8
57
 (1
1.0
)
0.
27
 (.0
4–
2.0
1)
I 4
,[5
],1
2:i
:–
28
2 
(7.
1)
76
2
24
5 
(32
.2)
0.
16
 (.0
4–
.69
)
Ja
v
ia
na
28
3 
(10
.7)
11
31
35
 (3
.1)
3.
76
 (1
.08
–1
3.0
4)
Po
on
a
26
2 
(7.
7)
14
6
4 
(2.
7)
2.
96
 (.5
1–
17
.05
)
Sa
in
tp
au
l
25
8 
(32
.0)
46
5
89
 (1
9.1
)
1.
99
 (.8
3–
4.7
5)
Sc
hw
ar
ze
n
gr
un
d
22
2 
(9.
1)
12
2
23
 (1
8.9
)
0.
43
 (.0
9–
1.9
7)
Sa
nd
ie
go
19
1 
(5.
3)
74
3 
(4.
1)
1.
32
 (.1
3–
13
.40
)
Pa
n
am
a
16
3 
(18
.8)
92
3 
(3.
3)
6.
85
 (1
.25
–3
7.5
8)
In
fa
n
tis
14
3 
(21
.4)
43
2
49
(11
.3)
2.
13
 (.5
7–
7.9
1)
Pa
ra
ty
ph
i B
 v
ar
 L
+ 
ta
rtr
at
e+
14
3 
(21
.4)
33
4
51
 (1
5.3
)
1.
51
 (.4
1–
5.6
1)
A
go
na
11
5 
(45
.5)
27
5
93
 (3
3.8
)
1.
63
 (.4
9–
5.4
8)
M
ue
nc
he
n
11
1 
(9.
1)
46
3
30
 (6
.5)
1.
44
 (.1
8–
11
.65
)
R
ub
isl
aw
10
0(0
)
89
1 
(1.
1)
N
/A
O
th
er
22
0
47
 (2
1.4
)
41
00
59
1 
(14
.4)
1.
61
 (1
.16
–2
.25
)
To
ta
l
11
89
32
1 
(27
.0)
19
 6
77
40
23
 (2
0.4
)
A
bb
re
v
ia
tio
ns
: C
I, 
co
nf
id
en
ce
 in
te
rv
al
; N
/A
, n
ot
 a
pp
lic
ab
le
; O
R,
 o
dd
s r
at
io
.
a A
ll 
iso
la
te
s w
ith
 re
sis
ta
nt
 a
nd
 in
te
rm
ed
ia
te
 m
in
im
um
 in
hi
bi
to
ry
 c
on
ce
nt
ra
tio
ns
 w
er
e 
ca
te
go
riz
ed
 a
s r
es
ist
an
t t
o 
re
m
ai
n 
in
 a
cc
or
da
nc
e 
w
ith
 c
lin
ic
al
 p
ra
ct
ic
e.
J Infect Dis. Author manuscript; available in PMC 2019 July 31.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Angelo et al. Page 13
Table 4.
Trend Effect of Year on Proportion of Nontyphoidal Salmonella Isolates Resistant to First-Line Treatment 
Agents, by Specimen Source and Agent, 2003–2013
OR (95% CI)
Agent Blood Isolates Stool Isolates
Ceftriaxone 1.12 (1.02–1.22) 0.95 (.92–.97)
Ciprofloxacin 1.09 (.99–1.20) 1.06 (1.03–1.10)
Trimethoprim-sulfamethoxazole 1.00 (.90–1.12) 0.97 (.93–1.01)
Ampicillin 0.97 (.92–1.02) 0.96 (.95–.98)
Abbreviations: CI, confidence interval; OR, odds ratio.
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